FibroGen Inc (NASDAQ:FGEN) insider K Peony Yu sold 7,500 shares of FibroGen stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $53.97, for a total transaction of $404,775.00. Following the transaction, the insider now owns 144,986 shares of the company’s stock, valued at approximately $7,824,894.42. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
K Peony Yu also recently made the following trade(s):
- On Monday, January 29th, K Peony Yu sold 10,000 shares of FibroGen stock. The shares were sold at an average price of $62.00, for a total transaction of $620,000.00.
- On Thursday, December 14th, K Peony Yu sold 2,851 shares of FibroGen stock. The shares were sold at an average price of $43.70, for a total transaction of $124,588.70.
Shares of FibroGen Inc (NASDAQ:FGEN) traded down $0.30 during mid-day trading on Friday, reaching $50.70. 852,809 shares of the company traded hands, compared to its average volume of 616,775. FibroGen Inc has a 1 year low of $22.75 and a 1 year high of $63.00. The company has a quick ratio of 10.83, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $4,190.00, a price-to-earnings ratio of -24.98 and a beta of 1.74.
A number of hedge funds have recently modified their holdings of FGEN. Janus Henderson Group PLC acquired a new position in FibroGen during the second quarter worth approximately $45,633,000. Eagle Asset Management Inc. purchased a new stake in FibroGen during the third quarter worth approximately $46,158,000. Vanguard Group Inc. grew its stake in FibroGen by 15.1% during the second quarter. Vanguard Group Inc. now owns 5,808,439 shares of the biopharmaceutical company’s stock worth $187,612,000 after buying an additional 761,421 shares during the period. First Trust Advisors LP grew its stake in FibroGen by 1,058.4% during the fourth quarter. First Trust Advisors LP now owns 776,640 shares of the biopharmaceutical company’s stock worth $36,813,000 after buying an additional 709,598 shares during the period. Finally, BlackRock Inc. grew its stake in FibroGen by 12.3% during the second quarter. BlackRock Inc. now owns 5,001,406 shares of the biopharmaceutical company’s stock worth $161,545,000 after buying an additional 546,587 shares during the period. 57.11% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have recently weighed in on FGEN shares. BidaskClub raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Thursday, December 21st. ValuEngine raised shares of FibroGen from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, Mizuho reaffirmed a “hold” rating and set a $61.00 price target on shares of FibroGen in a research report on Thursday, November 9th. Four analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $65.67.
TRADEMARK VIOLATION NOTICE: This article was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/02/09/fibrogen-inc-fgen-insider-k-peony-yu-sells-7500-shares.html.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.